Senvest Capital Inc. (SEC) 2020年年度报告「TSX」.pdf

1、SENVEST 2020 Annual Report Financial Highlights SELECTED FINANCIAL DATA(In thousands,except per share amounts)(years ended December 31)2020 2019 2018 2017 2016$SUMMARY OF OPERATIONS Total revenues and investment gains(loss)739,405 426,150(316,619)488,972 335,828 Net income(loss)attributable to commo

2、n shareholders 211,717 104,794(140,086)165,967 96,783 Diluted earnings(loss)per share 80.66 39.16(51.72)60.03 34.50 FINANCIAL DATA Total assets 4,065,992 2,884,999 2,756,970 2,976,026 2,563,217 Total equity 1,146,114 942,655 969,421 1,063,385 942,562 COMMON STOCK INFORMATION The companys common shar

3、es are listed on the Toronto Stock Exchange under the symbol SEC.2020 2019$FISCAL QUARTER High Low High Low First 183.00 100.00 190.00 162.99 Second 134.94 100.00 201.87 168.50 Third 142.00 121.00 185.00 156.01 Fourth 180.00 125.00 175.03 156.36 2,563,217 2,976,026 2,756,970 2,884,999 4,065,992 2016

4、2017201820192020Total Assets($thousands)942,362 1,063,385 969,421 942,655 1,146,114 20162017201820192020Total Equity($thousands)304.00344.00322.00347.00423.0020162017201820192020Book Value per Share1Senvest Capital Inc.Managements Discussion and Analysis December 31,2020 OVERALL PERFORMANCE Senvest

5、Capital(“Senvest”or the“Company”)had a strong finish to the 2020 year.From a net loss for the first nine months,the Company was able to achieve a net profit for the year based on its performance in the fourth quarter.The release of vaccination trial data by Pfizer/BioNTech and Moderna,which showed e

6、fficacy rates in the 95%range,caused equity markets to surge.The vaccines developed by these two companies,based on a novel technology platform using messenger RNA(mRNA),surprised markets with their high levels of efficacy.For the first time,hope for a solution to the COVID-19 pandemic and its impac